1. Home
  2. SPRO vs SEV Comparison

SPRO vs SEV Comparison

Compare SPRO & SEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$0.94

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Aptera Motors Corp.

SEV

Aptera Motors Corp.

HOLD

Current Price

$1.62

Market Cap

63.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
SEV
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
63.2M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
SPRO
SEV
Price
$0.94
$1.62
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$5.33
★ $6.33
AVG Volume (30 Days)
320.0K
★ 371.8K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
N/A
EPS
N/A
★ N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25,146.67
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$0.95
$1.29
52 Week High
$3.08
$7.00

Technical Indicators

Market Signals
Indicator
SPRO
SEV
Relative Strength Index (RSI) 34.32 45.32
Support Level N/A $1.51
Resistance Level $1.27 $2.06
Average True Range (ATR) 0.06 0.16
MACD -0.01 -0.02
Stochastic Oscillator 3.18 18.71

Price Performance

Historical Comparison
SPRO
SEV

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

Share on Social Networks: